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In mammals, a family of five acyl-CoA synthetases (ACSLs),
each the product of a separate gene, activates long chain fatty
acids to form acyl-CoAs. Because the ACSL isoforms have over-
lapping preferences for fatty acid chain length and saturation
and are expressed in many of the same tissues, the individual
function of each isoform has remained uncertain. Thus, we con-
structed a mouse model with a liver-specific knock-out of
ACSL1, a major ACSL isoform in liver. Eliminating ACSL1 in
liver resulted in a 50% decrease in total hepatic ACSL activity
and a 25–35% decrease in long chain acyl-CoA content.
Although the content of triacylglycerol was unchanged in
Acsl1L/ liver aftermicewere fed either low or high fat diets, in
isolated primary hepatocytes the absence of ACSL1 diminished
the incorporation of [14C]oleate into triacylglycerol. Further,
small but consistent increases were observed in the percentage
of 16:0 in phosphatidylcholine and phosphatidylethanolamine
and of 18:1 in phosphatidylethanolamine and lysophosphati-
dylcholine, whereas concomitant decreases were seen in 18:0
in phosphatidylcholine, phosphatidylethanolamine, phos-
phatidylserine, and lysophosphatidylcholine. In addition,
decreases in long chain acylcarnitine content and diminished
production of acid-soluble metabolites from [14C]oleate sug-
gested that hepaticACSL1 is important formitochondrial-ox-
idation of long chain fatty acids. Because the Acsl1L/ mice
were not protected fromdeveloping either high fat diet-induced
hepatic steatosis or insulin resistance, our study suggests that
lowering the content of hepatic acyl-CoAwithout a concomitant
decrease in triacylglycerol andother lipid intermediates is insuf-
ficient to protect against hepatic insulin resistance.
Acyl-CoA synthetase (ACSL)3 activates long chain fatty acid
(FA) to acyl-CoA, thereby enhancing vectorial FA transport
across the plasma membrane (1) and providing substrates for
most downstream pathways that metabolize FA. ACSL1 is one
of five ACSL isoforms, each encoded by a separate gene. Its
mRNA expression is highest in adipose tissue, liver, and heart
(2); and becauseAcsl1mRNA and total ACSL1 activity increase
160-fold (3) and 100-fold (4), respectively, in differentiating
3T3-L1 adipocytes, ACSL1 has been thought to be important in
activating FA destined for triacylglycerol (TAG) synthesis. In
support of this idea, overexpressing ACSL1 in mouse heart
increases cardiac myocyte TAG accumulation 12-fold and
induces apoptotic pathways, cardiac hypertrophy, left ventric-
ular dysfunction, and heart failure (5). However, Acsl1 mRNA
expression is up-regulated in liver and adipose tissue by activa-
tors of peroxisome proliferator-activated factor  (PPAR) (6,
7) via a PPAR response element in the promoter region ofAcsl1
(8), suggesting a possible function related to the -oxidation of
fatty acids. Moreover, overexpression of ACSL1 in rat primary
hepatocytes increases oleate incorporation into diacylglycerol
(DAG) but does not increaseTAGmass (9). Thus, the exact role
of ACSL1 in providing acyl-CoA for lipogenesis versus -oxi-
dation has remained uncertain.
It has been suggested that lipid intermediates, including FAs,
long chain acyl-CoAs, DAG, ceramide, and phosphatidic acid,
rather thanTAGaccumulation per se, might underlie the devel-
opment of insulin resistance (10–13). For example, long chain
acyl-CoAs directly affect glucose metabolism by allosterically
inhibiting glycogen synthase, pyruvate dehydrogenase, glu-
cose-6-phosphatase, and glucokinase (14, 15); and FAs or acyl-
CoAs may also be ligands for hepatocyte nuclear factor 4, a
transcription factor that regulates aspects of lipoprotein and
glucosemetabolism (16). Further,DAGactivates protein kinase
* This work was supported, in whole or in part, by National Institutes of Health
Grants DK59935 (to R. A. C.), DK40936 (to G. I. S.), U24 DK59635 (to G. I. S.),
P30 DK34987 (to G. I. S.), a grant from the American Diabetes Association
(to D. M. M.), a postdoctoral fellowship from the American Heart Associa-
tion Mid-Atlantic Region (to L. O. L.), Predoctoral Training Grant HL069768
in Integrative Vascular Biology (to J. M. E.) and P30 DK034987 and P30
DK056350.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Figs. 1 and 2 and supplemental Tables 1– 4.
1 Investigator of the Howard Hughes Medical Institute.
2 To whom correspondence should be addressed: Dept. of Nutrition, CB 7461,
University of North Carolina, Chapel Hill, NC 27599-7461. Tel.: 919-966-
7213; Fax: 919-843-8555; E-mail: rcoleman@unc.edu.
3 The abbreviations used are: ACSL, long chain acyl-CoA synthetase; AGPAT,
acylglycerol-3-phosphate acyltransferase; ANOVA, analysis of variance;
ASM, acid-soluble metabolite; CE, cholesteryl ester; DAG, diacylglycerol;
FA, fatty acid; FATP, fatty acid transport protein; GPAT, glycerol-3-phos-
phate acyltransferase; ITT, insulin tolerance test; LPA, lysophosphatidic
acid; LPC, lysophosphatidylcholine; neo, neomycin; OGTT, oral glucose tol-
erance test; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS,
phosphatidylserine; PPAR, peroxisome proliferator-activated factor; TAG,
triacylglycerol.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 284, NO. 41, pp. 27816 –27826, October 9, 2009
© 2009 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
27816 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284 • NUMBER 41 • OCTOBER 9, 2009
C isoforms that can phosphorylate insulin receptor substrates
on serine and threonine residues and thereby impair insulin
signaling (10). However, alterations of acyl-CoAs do not always
correlatewith changes in insulin sensitivity (17). Although acyl-
CoA content in muscle has been associated with diminished
insulin sensitivity (18), in liver the relationship between acyl-
CoAs and insulin sensitivity is less clear. For example, when
lipoprotein lipase is overexpressed and FA flux into the liver
from lipoprotein particles is increased, hepatic insulin resist-
ance is associated with an increased hepatic content of TAG
and acyl-CoA (19). However, when DAG acyltransferase-2 is
overexpressed in liver, the mice retain normal hepatic and
whole body insulin sensitivity despite hepatic steatosis and an
elevated acyl-CoA content (20). Similarly, the absence of glyc-
erol-3-phosphate acyltransferase 1 (Gpat1/) led to protec-
tion against hepatic insulin resistance despite a 64% increase in
hepatic acyl-CoA content, arguing against the importance of
long chain acyl-CoAs in promoting insulin resistance (17).
Although a higher content of acyl-CoAs might contribute to
insulin resistance in somemodels, it is not knownwhether pro-
tection against insulin resistancemight be achieved by decreas-
ing hepatic acyl-CoA content.
To understand the function of ACSL1 in liver, we con-
structed a mouse model with a liver-specific knock-out of
ACSL1 (Acsl1L/). Eliminating ACSL1 in liver resulted in a
50% decrease in total hepatic ACSL activity and a 25–35%
decrease in long chain acyl-CoA content. This model has
allowed us to determine whether ACSL1 deficiency protects
liver from hepatic steatosis and alters the incorporation of FAs
into specific glycerolipids and to learn whether a decrease in
long chain acyl-CoA content is sufficient to protect the liver
from high fat diet-induced insulin resistance.
EXPERIMENTAL PROCEDURES
Generation of Acsl1L/Mice—Liver-specific ACSL1 knock-
out mice (Acsl1L/) were created by LoxP-Cre strategy (21).
The gene-targeting vector was designed to produce a floxed
Acsl1 exon 2 (Fig. 1A) and was constructed in a standard plas-
mid backbone containing neomycin phosphotransferase (neo)
and thymidine kinase cassettes for positive and negative selec-
tion, respectively. The 5 arm of homology was 4.5 kb in length
andwas derived from intron 1, whereas the 3 armwas 3.8 kb in
length and derived from a portion of intron 2, exon 3, and a
portion of intron 3. Between the arms, a floxed exon 2 was
cloned. The targeting vector was electroporated into E14Tg2A
(E14) embryonic stem cells, and the cells were grown in
medium supplemented with G418 and gancyclovir. Targeted
cells were identified by PCR across both the 3 and 5 arms of
homology using primers specific to neo and primers flanking
the arms of homology. Neo was then excised from the targeted
allele via transient expression of flpE recombinase (Fig. 1B).
Targeted, neo-cells weremicroinjected into blastocysts derived
frommouse strain C57BL/6 to produce transmitting chimeras.
Twenty-one high quality chimeras were produced that trans-
mitted the targeted allele. Duplex PCR was performed to dis-
tinguishwild-type and Flox alleles withwild-type specific prim-
ers (forward, 5-AGCAAGCCACATGAAGGCATGT-
GTG-3 and reverse, 5-AAGTGGGGGACATAGGTGCCACT-
3) and LoxP-specific primers (forward, 5-TAGAAAGTATA-
GGAACTTCGGCGCG-3 and reverse, 5-GCCCCTATATC-
ACTTTTGGCGACA-3). Mice heterozygous for the targeted
allele (Acsl1Flox/) were identified and back-crossed six times
to C57BL/6 mice. The established Acsl1Flox/ mice were
then crossed with rat albumin promoter-Cre transgenic mice
(Alb-CreTg/0), which express Cre recombinase exclusively in
postpartum liver (22). The resulting double heterozygous mice
carrying one floxed allele and Alb-Cre recombinase (Acsl1Flox/-
Alb-CreTg/0, i.e. ACSL1 heterozygote) were interbred to yield
Acsl1L/ mice (Acsl1Flox/Flox-Alb-CreTg/0), as well as five dif-
ferent groups of littermate controls (Fig. 1C). The presence or
absence of the Alb-Cre transgene was determined by duplex
PCR using Cre-specific primers (forward, 5-GCGGTCTGGC-
AGTAAAAACTATC-3 and reverse, 5-GTGAAACAGCAT-
TGCTGTCACTT-3) and IL-2 as internal control for amplifi-
cation (forward, 5-CATGGCCACAGAATTGAAAGA-
TCT-3 and reverse, 5-GTAGGTGGAAATTCTAGCATCA-
TCC-3) (Fig. 1C). To confirm the knock-out of exon 2 in
Acsl1L/ mice, total RNAwas extracted (Qiagen RNeasyMini
kit) from Acsl1L/ mice and control mice, and cDNA was
synthesized by reverse transcription (Applied Biosystems).
PCRwas conducted with forward primer 5-GCGGAGGAGA-
ATTCTGCATAGAGAA-3 and reverse primer 5-ATATCA-
GCACATCATCTGTGGAAG-3. PCR amplification of the
region between coding exon 1 and exon 10 yielded a band of1
kb in control mice and a smaller band of 900 bp in Acsl1L/
mice (Fig. 1D). DNA sequencing (University of North Carolina
Genome Analysis Facility) of the purified bands (QIAquick gel
extraction kit) showed that in Acsl1L/ mice, exon 1 was fol-
lowed immediately by exon 3, proving that the shorter PCR
product in Acsl1L/ mice was due to the missing exon 2 (118
bp). The absence of exon 2 causes a frameshift and introduces a
stop codon (TAG) immediately after exon 1, resulting a trun-
cated peptide of 70 amino acids in the Acsl1L/ mice com-
pared with a 699-amino acid protein in the control mice
(sequence not shown).
Animal Experiments—Malemice (age 12–17weeks)were fed
a standard diet (Prolab Isopro RMH 3000, LabDiet) and killed
after either a 4-h or a 24-h fast unless otherwise indicated.
Plasma was collected from the retroorbital sinus. Liver, heart,
and adipose tissues were snap frozen in liquid nitrogen and
stored at 80 °C. For high fat diet studies, 8-week-old
Acsl1L/ and control (Acsl1Flox/Flox) mice were fed a high fat
Western diet (45% calories from fat (mostly lard), 35% from
carbohydrate (sucrose and corn starch) Research Diets
D12451) or an isocaloric standard control diet (10% calories
from fat (lard and soybean oil), 70% from carbohydrate (sucrose
and corn starch) Research Diets D12450B) for 14–18 weeks.
Mice were weighed weekly. Body composition was determined
by magnetic resonance imaging. At 25 weeks, mice were
killed, and tissues were snap frozen in liquid nitrogen and ana-
lyzed for enzyme activity, quantitative real time-PCR, Western
blotting, and lipid content.
Primary Hepatocyte Culture and Oleate Labeling—Primary
hepatocytes were obtained from fed 12-week-old male
Acsl1Flox/Flox andAcsl1L/mice, by in situ liver perfusion using a
modification of the collagenase method (23). Briefly, the livers
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were first perfused with a Ca2-free perfusion buffer (10 mM
HEPES, 132 mM NaCl, 20 mM dextrose, 6.7 mM KCl, 1 mM aden-
osine, 1.5 mM NaOH, 0.1 mM EGTA, 0.02 unit/ml insulin) and
then with Ca2-containing collagenase buffer (0.3 mg/ml; type
CLS I, 230 units/ml; Worthington, Lakewood, NJ). Hepatocytes
were collected after low speed centrifugation and seeded (1.0 
106 cells/60-mm dishes) onto collagen-coated plates as described
previously (9). Thenext day, hepatocyteswere labeledwith 2ml of
medium containing 0.5 Ci of [1-14C]oleate (final concentration,
500 M oleate) for 3 h and then collected for cellular lipid extrac-
tion (24) andmediumacid-solublemetabolites (ASMs) as ameas-
ure of incomplete FA oxidation (9). Lipid extracts were separated
by thin layer chromatography inhexane:ethyl ether:acetic acid (80:
20:1, v/v). The 14C-labeled lipids were detected and quantified
with a Bioscan 200 imaging system.
Glucose and Insulin Tolerance Tests—Oral glucose tolerance
tests (OGTTs) and insulin tolerance tests (ITTs) were per-
formed in 5-month-old mice (after 3 months of high fat or
control diet feeding). Mice were fasted for 4 h after the start of
the light cycle and gavaged with glucose (2.5 g/kg) for OGTTs
or injected intraperitoneally with insulin (0.75 unit/kg) for
ITTs. Blood glucose was determined before and 15, 30, 60, 90,
and 120min after the glucose or insulin load with a glucometer
(LifeScan, Inc.) (25).
Euglycemic-Hyperinsulinemic Glucose Clamp Experiments—
In 11–13-week-old mice that had been fed a high fat (safflower
oil) diet for the preceding 3 weeks, clamp studies were per-
formed as described previously (17) with a prime-continuous
[3-3H]glucose infusion 10-Ci bolus, 0.1 Ci/min) to deter-
mine rates of whole body glucose turnover followed by a
primed-continuous insulin infusion (2.5 milliunits/kg/min;
Humulin, Eli Lilly, Indianapolis, IN) to raise insulin levels
within a physiologic range. A single 2-deoxy-D-[1-14C]glucose
injection was administered at 75 min.
Liver Insulin Signaling—Male mice (5 months old) were
fasted overnight (16 h) and anesthetized with Avertin. Insulin
FIGURE 1. Targeted disruption of the mouse ACSL1 gene in liver. A, ACSL1 conditional gene targeting. The targeting construct was designed to delete exon
2 of the ACSL1 gene when crossed to Cre-expressing animals. With excision of exon 2, splicing from exon 1 to downstream exons results in reading frame shifts
and immediate translational stops. The positive selection marker (neo) was flanked by frt sites. Both neo and the target region were flanked by loxP sites. The
vector also contained the thymidine kinase (TK) gene, allowing for positive-negative selection. B, ACSL1 FlpE/Cre-mediated excisions. Targeted cells were
transiently transfected with a FlpE expression vector and screened for the loss of neo by PCR and by cell death when G418 was present in the medium. Targeted
neo cells were microinjected into blastocysts to produce transmitting chimeras. Cre recombinase eliminates exon 2. C, PCR amplification of loxP sites and
Alb-Cre recombinase. Double heterozygous mice carrying one floxed allele and Alb-Cre recombinase (Acsl1Flox/-Alb-CreTg/0, i.e. ACSL1 heterozygote) were
interbred to obtain Acsl1L/ mice along with five different groups of littermates. Duplex PCR yielded a 780 bp band for wild type allele and a 380 bp band for
LoxP allele (upper panel). Another duplex PCR yielded a 324 bp band for internal control and a 100 bp band for Alb-Cre recombinase (lower panel). Lanes 4 show
bands from an Acsl1L/ mouse (Acsl1Flox/Flox-Alb-CreTg/0). D, PCR amplification of the region between exon 1 and exon 10. cDNA was synthesized from total RNA
that was extracted from control and Acsl1L/ mice. PCR with primers that bind exon 1 and exon 10 yielded a shorter band in Acsl1L/ mice. Sequencing of the
PCR products confirms that the sizes were 996 bp and 878 bp for control and Acsl1L/ mice, respectively, and exon 2 (118 bp) was missing in Acsl1L/ mice.
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(1 unit/kg of body weight) or phosphate-buffered saline was
injected via the portal vein. Twomin later, the left liver lobewas
snap frozen in liquid nitrogen. Liver tissue was pulverized and
homogenized on ice in a HEPES buffer (pH 7.4) containing 1%
Nonidet P-40, 100 mM NaCl, 2% glycerol, 5 mM NaF, 1 mM
EDTA, and proteinase inhibitor mixture and phosphatase
inhibitor cocktails I and II (Sigma). Homogenates were centri-
fuged at 16,000  g for 30 min at 4 °C, and supernatants were
used for Western blotting with antibody against phosphoryla-
ted AKT.
Western Blotting—ACSL1 expression was determined in
liver, gonadal adipose tissue, and heart using a polyclonal pep-
tide antibody (a gift from Cell Signaling, 4047). Homogenates
from liver and heart or total particulate from gonadal adipose
tissuewas separated by electrophoresis on an 10%polyacrylam-
ide gel. Phosphorylation of AKT (Ser-473) was determined in
the liver supernatant after injection of insulin through the por-
tal vein. Anti-phospho-AKT (Ser-473) and anti-AKT were
from Cell Signaling. Adobe Photoshop software was used for
densitometry analysis.
ACSL, GPAT, and Acylglycerol-3-phosphate Acyltransferase
(AGPAT) Activities—Initial rates of total ACSL activity in liver
homogenates were measured with 2–4 g of liver homogenate
at 37 °C in the presence of 175mMTris (pH 7.4), 8mMMgCl2, 5
mM dithiothreitol, 10 mM ATP, 250 M CoA, 50 M
[1-14C]palmitic acid in 500 MTriton X-100, and 10 M EDTA
in a total volume of 200 l (9). GPAT specific activity was
assayed with 20–40 g of liver homogenate at room tempera-
ture in a 200-l reaction mixture containing 75 mM Tris-HCl
(pH 7.5), 4 mM MgCl2, 1 mg/ml bovine serum albumin (essen-
tially FA-free), 1mMdithiothreitol, 8mMNaF, 800M [3H]glyc-
erol 3-phosphate, and 80 M palmitoyl-CoA (26). AGPAT
activity was determined bymeasuring the conversion of [3H]ly-
sophosphatidic acid (LPA) to [3H]phosphatidic acid in a 200-l
reaction mixture containing 100 mM Tris-HCl (pH 7.4), 10 M
oleoyl-LPA, 50 M oleoyl-CoA, 0.25 Ci of [3H]oleoyl-LPA,
and 1 mg/ml bovine serum albumin (essentially FA-free) (27).
The reaction was started by adding 0.2–0.8 g of liver total
particulate followed by incubation for 6 min at 37 °C.
Liver and Plasma Metabolites—Lipids were extracted by a
modified Folch method (28, 29), and liver TAG (Stanbio) and
total cholesterol (Wako) mass were determined enzymatically.
To determine hepatic lipid metabolite profiles, liver (100 mg)
was homogenized with appropriate internal standards in spe-
cific organic reagents (17). After separation, purification, and
elution, lipid metabolite extracts were separated by high per-
formance liquid chromatography, and individual and total lipid
species were analyzed by liquid chromatography/tandemmass
spectrometry (17). Liver glycogen was extracted and digested
with amyloglucosidase for 30 min at 37 °C (30). Glucose con-
centration was determined using the Glucose Autokit CII assay
(Wako). For acylcarnitine species,malemice fed a standard diet
were fasted 48 h before liverswere collected. Specimens of pow-
dered liver were homogenized in deionized water and
extracted, and acylcarnitine species were measured by direct
injection electrospray tandem mass spectrometry (31). For
plasma chemistries and lipids, after Avertin anesthesia, blood
was obtained from the tail vein or the retroorbital venous
plexus. Plasma glucose, TAG, total cholesterol, free FA, -hy-
droxybutyrate (Wako, Stanbio) and insulin (RocheApplied Sci-
ence) were determined with commercially available kits (32).
RNA Extraction and Quantitative Real Time PCR Assay—
Total liver RNA was isolated using the RNeasy Plus Mini kit
(Qiagen), and 20 g of total RNA was reverse transcribed to
cDNA using the high capacity cDNA reverse transcription kit
(Applied Biosystems). Quantitative PCR was performed with
the iCycler Thermal Cycler instrument (Bio-Rad) in 25l using
SYBR Green fluorescein reagent mix and 10 nM fluorescein as
the calibration dye (Applied Biosystems). Each reaction con-
tained cDNAderived from 20 ng of total RNA.Oligonucleotide
primers were designed using the Primer-BLAST program
(National Center for Biotechnology Information). Sequences of
primers are listed in supplemental Table 1. The fold change in
expression of the target genes was normalized to the endoge-
nous control (-actin) andwas calculated relative to the control
group using the 2CT method (33).
Statistical Analysis—Values are expressed as means  S.E.
Statistical comparisons between control and ACSL1 knock-out
micewere determined using an unpaired, two-tailed Student’s t
test. Statistically significant effects of diet and genotype were
identified using a two-way analysis of variance (ANOVA) with
interaction. A p value  0.05 was considered significant unless
otherwise indicated.
RESULTS
Generation of Liver-specific ACSL1 Knock-out Mice
(Acsl1L/)—The generation of targeting vector, embryonic
stem cells containing floxed Acsl1 allele, and chimeras was
described under “Experimental Procedures.” Acsl1L/ mice
(Acsl1Flox/Flox-Alb-CreTg/0) were produced by interbreeding
double heterozygotes (Fig. 1C). For the experiments described,
Acsl1L/ were crossed with Acsl1Flox/Flox littermates lacking
the Alb-Cre transgene (Acsl1Flox/Flox-Alb-Cre0/0) to yield
Acsl1L/ mice and Acsl1Flox/Flox mice. These two genotypes
were born at the expected frequency (1:1), indicating that the
combination of the floxed allele and the Cre transgene did not
affect reproduction. Acsl1Flox/Flox mice were used as controls
because pilot studies showed that neither the loxP sites nor the
presence of albumin-Cre altered ACSL1 expression or pheno-
type (data not shown).
Liver-specific Deletion of ACSL1 (Acsl1L/)—Acsl1 mRNA
was virtually absent in Acsl1L/ liver, confirming the ACSL1
deletion (Fig. 2A). No difference was observed for the mRNA
from the other two major ACSL isoforms in liver, Acsl4 and
Acsl5. The increase in the mRNA amount of the less abundant
ACSL isoform, Acsl3, was not significant. The mRNA abun-
dance for fatty acid transport proteins FATP2, 4, and 5, which
have very long chain acyl-CoA synthetase activity, also
remained unchanged in Acsl1L/ liver.
Using a rabbit peptide antibody against human ACSL1, we
detected a 75 kDa band in liver from control liver, but not in
liver from Acsl1L/ mice, whereas the band was present in
gonadal adipose tissue and heart from both control and knock-
out mice, indicating that the deletion of ACSL1 was specific to
liver (Fig. 2B). Consistent with the quantitative real time-PCR
andWestern blotting results, total ACSL activity in liver homo-
Liver-specific Acyl-CoA Synthetase-1 Knock-out
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genates was 56 and 47% lower than in control male and female
mice, respectively (Fig. 2C). This decrease in ACSL activity
indicates that ACSL1 contributes approximately 50% of total
ACSL activity in liver and that other ACSL isoforms did not
compensate for the loss. The remainingACSL activity probably
represents activity from other ACSL and FATP isoforms pres-
ent in liver.
At 12–14 weeks, Acsl1L/ mice showed no significant dif-
ference from control mice for body weight, organ weights, adi-
posity, or plasma metabolites (supplemental Table 2). Because
it has been reported that ACSL1 is up-regulated by PPAR, a
transcription factor that increases FA -oxidation (6, 7), we
compared Acsl1L/ and control mice after a 24-h fast. After a
24-h fast, both knock-out and control mice lost approximately
3 g of body weight and had similar changes in blood glucose,
insulin, TAG, total cholesterol, ketone bodies, and hepatic gly-
cogen (supplemental Table 3). No difference was observed
when the 12–14-week-old mice were subjected to OGTTs and
ITTs (data not shown), suggesting that ACSL1 deficiency in
liver did not affect glucose metabolism.
Acsl1L/ Liver Contained Less Acyl-CoA—ACSL isoforms
provide acyl-CoAs, not only for lipid metabolism, but also for
lipid intermediates that are important for cell signaling. Previ-
ous studies have suggested that acyl-CoAs and DAG might
affect insulin sensitivity in skeletal muscle and liver (10). To
examine the effect of a deficiency of ACSL1 in liver, the
amounts and composition of the FA-derived lipid intermedi-
ates, acyl-CoAs, LPA, and DAG were measured in mice fed
matched low and high fat diets. The high fat diet contained 45%
calories from predominantly saturated fat. As might be ex-
pected with a 56% decrease in hepatic ACSL activity in male
Acsl1L/ mice, both the amount and major species of acyl-
CoA were affected. In both genotypes, the high fat diet
increased the total and all major acyl-CoAs except C16:1-CoA
and C18:1-CoA (Fig. 3A). When fed either the control or the
high fat diet, the content of acyl-CoA in knock-out mice liver
was 35 and 25% lower, respectively, than in liver from control
mice (Table 1). Themajor acyl-CoA in liver, C18:1-CoA,was 42
and 29% lower in knock-out mice fed the control diet or the
high fat diet, respectively (Fig. 3A). The decreases in multiple
acyl-CoA species are consistent with the broad substrate range
of ACSL1 (34).
Despite the lower content of acyl-CoA, liver from Acsl1L/
mice fed the high fat diet contained 52% more total LPA and
42% more C16:0-LPA than control liver (Fig. 3B). The 314 and
49% higher C18:0-LPA and C16:1-LPA were also close to sta-
tistical significance (p 	 0.06, and p 	 0.08, respectively). We
measured themRNA abundance and enzyme activity of GPAT,
the enzyme that uses glycerol 3-phosphate and acyl-CoA to
form LPA. For the four known GPAT isoforms, none of the
changes in mRNA abundance was significant (includingGpat3
(p 	 0.09) (Fig. 3C). Similarly, the 11% increase in total GPAT
activity was not statistically significant (p 	 0.06, 1.96  0.07
nmol/min/mg of protein in control versus 2.17  0.07 nmol/
min/mg of protein in knock-out liver). Because the increase in
LPA might also have been caused by a decrease in its metabo-
lism, we measured the activity of AGPAT, which acylates LPA
to form phosphatidic acid. No significant difference was found
between control and knock-out mice (data not shown). Thus,
the increase in LPA in Acsl1L/ liver from high fat diet-fed
mice remains unexplained. Total hepatic LPA content in mice
fed the standard diet was similar in the two genotypes (Table 1).
The decrease in total acyl-CoA content did not affect the
hepatic content of DAG in Acsl1L/ liver, which was similar
for both genotypes, when mice were fed either the control diet
or the high fat diet (Fig. 3D and Table 1). The Acsl1L/ DAG
composition was similar to that of control mice, except for 27
and 21% less C18:0/C18:0-DAG and C18:0/C16:0-DAG,
respectively, when mice were fed the control diet, and 27 and
44% less C18:1/C18:2-DAG and C18:2/C18:2-DAG, respec-
tively, when mice were fed the high fat diet (Fig. 3D).
Incorporation ofOleate intoHepatocyte TAGandLongChain
FA Oxidation Were Impaired with ACSL1 Deficiency—Based
on substrate preferences, tissue location, subcellular location,
and different sensitivity to inhibitors, we had hypothesized pre-
FIGURE 2. Acsl1L/ liver contains little Acsl1 mRNA, no ACSL1 protein,
and decreased ACSL activity. A, relative gene expression of Acsl and Fatp in
Acsl1L/ liver (n 	 6 for each group). Total RNA was isolated from liver, and
20 g was synthesized to cDNA for SYBR Green quantitative PCR. Target gene
expression was normalized to the endogenous control -actin and expressed
as 2CT relative to the control. B, ACSL1 protein expression in the liver,
heart, and adipose tissue of Acsl1L/ mice. Extracts from 100 g of liver,
gonadal white adipose tissue, or heart were subjected to SDS-PAGE (10% gel).
The proteins were transferred to a polyvinylidene difluoride membrane and
probed with anti-ACSL1 peptide polyclonal antibody to detect endogenous
ACSL1. This representative result was repeated four times. C, ACSL specific
activity in liver. Homogenates from control and Acsl1L/ liver were
assayed in the presence of 50 M [1-14C]palmitic acid. Data show means 
S.E. from 5 to 7 mice/group. **, p  0.0001 versus control mice (Student’s t
test).
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viously that each ACSL isoform provides acyl-CoAs destined
for specific downstream pathways (35). Despite the normal
liver content of TAG, when hepatocytes from control and
Acsl1L/ mice were incubated with [14C]oleate, the incorpo-
ration of the fatty acid into TAG was 20% lower in the knock-
out cells (Fig. 4A). Labeled medium ASM, the product of
incomplete FAoxidation,was 4.5% lower in the knock-out cells.
In addition, [14C]oleate uptake into isolated Acsl1L/ hepato-
cytes during a 2-min uptake experiment was similar to that of
controls (data not shown). Further,Acsl1L/ and controlmice
had similar plasma -hydroxybutyrate concentrations after
they were fed, fasted for 24 h, or fed with the high fat diet
(supplemental Tables 1–3).However, a comprehensive analysis
of the liver acylcarnitine species by tandemmass spectrometry
showed that Acsl1L/ liver contained 50%, 58%, and 55% less
C18:2-carnitine, C18:1-carnitine, and C18:0-OH, respectively,
and twice asmuch C8:0-carnitine (Fig. 4B). Long chain acylcar-
nitines are mitochondrial intermediates that are derived
directly from their corresponding acyl-CoAs and thus reflect
the flux of FA through mitochondrial FA oxidation (31). The
decreases in long chain acylcarnitines were consistent with the
lower incorporation of label from [14C]oleate into ASM and
suggested that long chain FA oxidation in liver is impaired by
ACSL1 deficiency. The increase in C8:0-carnitine, in contrast,
suggested that peroxisomal FA oxidation had increased, and
themRNA for acyl-CoAoxidase 1, a key enzyme in peroxisomal
oxidation, was 91% higher in Acsl1L/ liver.
Phospholipid Composition Was Altered in Acsl1L/ Liver—
Because in vitro assays with purified ACSL1 showed activation
of a broad range of saturated and unsaturated fatty acids with
little apparent difference in FA preference (36, 37), the lipid
profile inAcsl1L/ liver was examined to determine whether a
preference would be expressed in vivo. When fed the high fat
diet, TAG increased in both genotypes, and Acsl1L/ liver
contained more DAG, FA, and lysophosphatidylcholine (Fig.
5). In Acsl1L/ liver, small but significant differences were
observed in the distribution of specific FAs in several phospho-
lipid species. Acsl1L/ liver PC and PE contained a higher
percentage of C16:0, and PC, PE, and PS contained a lower
percentage of C18:0 compared with control mice (Fig. 6,
A–C). Compared with phospholipids in control liver,
Acsl1L/ liver LPC contained more C16:0 and C18:1 and less
C18:0 and C20:4 (Fig. 6E). Few differences were observed in the
genotypes for cardiolipin FA composition (Fig. 6D). These
FIGURE 3. Acsl1L/ liver contained less acyl-CoA than control liver. Control and Acsl1L/ mice were fed a 45% fat diet (HFD, Research Diets D12451) or a
matched 10% fat control diet (SD, Research Diets D12450B) from 8 to 23 weeks of age. Liver samples were snap frozen after the mice were fasted for 4 h. Lipid
intermediates were extracted and measured by tandem mass spectrometry. A, total long chain acyl-CoA and acyl-CoA species. B, total long chain LPA and LPA
species. C, relative expression of Gpat isoform mRNA in Acsl1L/ liver (n 	 6 for each group). Total RNA was isolated from liver, and 20 g was synthesized to
cDNA for SYBR Green quantitative PCR. Target gene expression was normalized to the endogenous control -actin and expressed as 2CT relative to the
control. D, total DAG and DAG species. Data show means  S.E. from 10 mice/group. B, *, p  0.05 versus control mice (Student’s t test). A and C, *, p  0.05; **,
p  0.01 versus control mice fed the same diet (two-way ANOVA); #, p  0.05; ##, p  0.01 versus 10% fat control diet in the same genotype (two-way ANOVA).
TABLE 1
Liver lipid metabolites from Acsl1L/ and Acsl1Flox/Flox mice fed a high fat or a control diet for 14 –18 weeks
Samples were obtained after a 4-h fast. Data represent means  S.E. The number of animals in each group is indicated in parentheses. KO, knock-out.
Total liver lipid metabolites
10% fat diet (control) 45% fat diet (high fat)
Control (n  10) KO (n  10) Control (n  10) KO (n  10)
Acyl-CoA (nmol/g liver) 30.1  0.5 19.4  0.4a 40.2  0.9b 30.4  0.6a,b
Lysophosphatidic acid (nmol/g liver) 2.69  0.14 2.19  0.32 2.52  0.24 3.82  0.44c
Diacylglycerol (nmol/g liver) 949  88 863  98 957  147 966  123
a p  0.01 compared with control mice fed the same diet (two-way ANOVA).
b p  0.01 compared with 10% fat control diet in the same genotype (two-way ANOVA).
c p  0.05 compared with control mice (Student’s t test).
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lower percentages of C18:0 in Acsl1L/ liver phospholipids
were also present after the mice were fed a high fat diet for 3
months, suggesting that ACSL1 makes a specific contribution
of 18:0-CoAs to phospholipid composition either during de
novo synthesis or during FA recycling.
Unlike the changes in phospholipids, the hepatic content of
neutral lipids, including CE and TAG, did not change signifi-
cantly in Acsl1L/ liver (Fig. 7).
High fat diet feeding decreased the
percentages of C16:1 and C18:1n7
in TAG in both control and knock-
out mice, but no difference between
genotype was observed. Acsl1L/
liver contained a lower percentage
of C20:4 and C22:6 in TAG and
tended to have lower percentage of
C18:2 TAG (p 	 0.05) when fed the
high fat diet. These data indicate
that neither a 50% decrease in total
ACS activity nor a specific defi-
ciency of ACSL1 alters the predom-
inant TAG species.
ACSL1 Deficiency Did Not Pro-
tect Mice from Developing Insulin
Resistance—Because the Acsl1L/
liver contained 25–35% less acyl-
CoA than control mice, we ques-
tioned whether Acsl1L/ mice
would be protected from develop-
ing hepatic and whole-body insulin
resistance. OGTTs and ITTs were
performed inmice fed a high fat diet
for 3 months. Compared with mice
fed the control diet, mice fed the
high fat diet had higher peak blood
glucose levels and a larger area
under the curve during the OGTTs,
and but no differences between gen-
otypes were observed in either the
OGTTs or the ITTs (supplemental
Fig. 1, A and B, respectively).
To examine the possibility that
long term feeding might cause a
compensatory adaptation, we examined the tissue and whole
body insulin sensitivity using euglycemic-hyperinsulinemic
clamp experiments in young mice (11–13 weeks) after they
were fed a high fat (safflower oil) diet for 3 weeks. Hepatic
ACSL1 deficiency had no effect on hepatic and whole body
insulin sensitivity, hepatic glucose production, or peripheral
glucose utilization (Fig. 8). Thus, a hepatic ACSL1 deficiency
did not protect the mice from diet-induced whole body or
hepatic insulin resistance. Further, direct insulin injection into
the portal vein increasedAkt Ser-473 phosphorylation similarly
in control and knock-outmice (supplemental Fig. 2), consistent
with the interpretation that the 25–35% lower hepatic acyl-
CoA content observed in the knock-out liver (Table 1) did not
enhance hepatic insulin signaling.
DISCUSSION
Long chain ACS isoforms activate FAs of between 10 and 22
carbons and provide acyl-CoAs for lipid synthesis, lipid oxida-
tion, and lipid signaling. Since the discovery of the first ACSL
isoform, ACSL1, in 1990 (36), four additional mammalian
ACSL isoforms have been identified, each with several splice
variants (38). Major progress has been made in our knowledge
FIGURE 4. ACSL1 deficiency decreased [1-14C]oleate incorporation into cell TAG and medium ASM, and
liver contained fewer long chain acylcarnitines. A, primary hepatocytes were isolated from 12-week-old
control and Acsl1L/ mice after collagenase perfusion. Cells (1  106 cells/60-mm dish) were incubated with
500 M [1-14C]oleate for 3 h and harvested, and medium was collected for ASMs, for the products of incomplete
FA oxidation. [1-14C]Oleate incorporation into neutral lipid species was determined as described under “Exper-
imental Procedures.” Data are reported as means  S.E. from a representative experiment performed in tripli-
cate dishes. *, p  0.05; **, p  0.01; ***, p  0.001. B, male mice fed a chow diet (Prolab Isopro RMH 3000) were
fasted for 48 h before livers were collected. Acylcarnitine species were analyzed by tandem mass spectrometry.
DC, dicarboxylated acylcarnitines; OH, hydroxylated acylcarnitines. Data show means  S.E. for four animals/
group. *, p  0.05 for Acsl1L/ mice versus control mice.
FIGURE 5. Changes in neutral and phospholipids in livers from Acsl1L/
and control mice fed control and high fat diets. Lipid classes from livers of
mice fed a high fat diet (HFD) or a control diet (SD) for 14 weeks were extracted
and analyzed (Lipomics Technologies, Inc). Data show means  S.E. from five
mice/group. *, p  0.05 versus 10% fat control diet in the same genotype
(two-way ANOVA). CL, cardiolipin; FC, free cholesterol.
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of ACSL primary structure, enzymatic kinetics, tissue distribu-
tion, subcellular location, and nutritional regulation. However,
because no specific inhibitors for individual ACSL isoforms
have been identified, the exact role of each ACSL in lipid
metabolism and lipid signaling remained unknown. We
hypothesized previously that specific ACSL isoforms provide
acyl-CoAs for particular metabolic pathways and that individ-
ual ACSL isoforms might have tissue-specific functions. Sup-
porting evidence includes in vitro overexpression studies of
ACSL1 and ACSL5 (9, 39). Overexpressing ACSL1 in primary
hepatocytes increases the incorporation of oleate intoDAGand
phospholipid and decreases incorporation into CE but has no
effect onTAG. In contrast, overexpressingACSL5 in hepatoma
cells partitions exogenous FA toward TAG synthesis and stor-
age but not toward phospholipid or CE synthesis. However,
gain-of-function studies are fraught with possible ambiguities.
The overexpressed protein may be mislocated, or the overex-
pressed enzymatic product may overwhelm the capacity of
downstream metabolic pathways. Thus, we constructed a
mouse deficient in ACSL1 in liver to elucidate the role of
ACSL1 in hepatic metabolism.
Using the LoxP-Cre strategy, we knocked out the Acsl1L/
gene specifically in liver, demonstrated by the absence of the
exon 2 sequence, the
94% knockdown ofAcsl1L/mRNAby
quantitative real time-PCR, and the absence of ACSL1 protein.
The specific activity of ACSL in liver was 50% lower than in
controls, confirming that ACSL1 is a major hepatic ACSL iso-
form.Changes inmRNA from the othermajorACSL and FATP
isoforms were not significant, and the loss of ACSL specific
activity suggested that a complementary increase of other pro-
teins with ACSL activity had not occurred. Overall, the lack of
ACSL1 and 50% of ACSL activity in liver did not have a major
effect onmouse phenotype, viability, adiposity, or growth. Liver
and adipose tissues were of normal weight, and the plasma con-
centrations of FA, TAG, total cholesterol, and fasting ketone
bodies did not change.
The ability of ACSL to convert lipophilic FAs into water-
soluble acyl-CoAs that are trapped within cells stimulated the
concept that proteins with ACSL activity might facilitate cellu-
lar FA uptake (1). In fact, ACSL1 was identified in an unbiased
search designed to clone proteins that increase the uptake of
long chain FAs into cells (40). However, when overexpressed
FIGURE 6. FA composition of phospholipids from Acsl1L/ and control livers. PC (A), PE (B), PS (C), CL (D), and LPC (E) from livers of mice fed a high fat diet (HFD)
or a control diet (SD) for 14 weeks were extracted and analyzed (Lipomics Technologies, Inc.). Data show means  S.E. from five mice/group. *, p  0.05; **, p  0.01
versus control mice fed the same diet (two-way ANOVA). #, p  0.05; ##, p  0.01 versus 10% fat control diet in the same genotype (two-way ANOVA). CL, cardiolipin.
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3.7-fold in rat primary hepatocytes, ACSL1 did not increase
total metabolized FA (9), either because ACSL1 does not
enhance FAuptake in hepatocytes or because this gain-of-func-
tionmodel could not further increase an already high basal rate
of FA uptake. In the present study, the 25–35% lower total acyl-
CoAandmajor acyl-CoA species in theAcsl1L/ liver could be
due solely to the decrease in ACSL activity or to the combined
effect of decreased ACSL activity and decreased ACSL1-medi-
ated FA uptake. Arguing against the latter possibility is the
observation that plasma nonesterified FA concentrations were
similar in control and Acsl1L/ mice under all conditions
tested and the finding that FA uptake was similar in control
and Acsl1L/ hepatocytes. Further, cellular FA content was
unchanged or increased in Acsl1L/ liver.
The major findings in the liver-specific Acsl1L/ mice were
the changes in phospholipid FA composition and the decreases
in TAG and ASM synthesis by isolated hepatocytes. The
observed relative increases in C16:0 and C18:1 and decreases in
C18:0 and C20:4 in several phospholipid species point out lim-
itations in drawing conclusions about substrate preference
based on in vitro assays. Thus, the reported FA preferences of
purified ACSL1 (37) did not predict the changes in actual FA
composition observed in liver phospholipids, a composition
that likely depends on substrate availability, enzyme affinity,
and lysophospholipid acyltransferases activities. Further, one
would not have predicted that FA compositionwould change in
only some glycerolipids, such as LPC, PC, and PE, but not in
others, such as TAG, and that diet would have so little influence
on FA composition.
With regard to TAG synthesis, the function of ACSL1 in
liver has been unclear. On the one hand, hepatic Acsl1
mRNA is higher in obese and hypertriglyceridemic rats with
fatty livers (41, 42), suggesting a link with TAG synthesis.
However, PPAR ligands that stimulate genes required for
FA -oxidation strongly induce hepatic Acsl1 mRNA (6, 7)
via a PPAR response element in the gene promoter (8).
Moreover, ACSL1 is located both in liver endoplasmic retic-
ulum (43) and in mitochondria (44), the organelles respon-
sible for TAG synthesis and FA -oxidation, respectively.
Experimentally, overexpressed ACSL1 in NIH 3T3 fibro-
blasts, mouse heart, or mouse liver increased TAG synthesis
(5, 45, 46), but adenovirus-mediated overexpression in rat
primary hepatocytes did not affect oleate incorporation into
TAG (9), and siRNA targeting of Acsl1 in human hepatoma
Huh7 cells did not alter oleate incorporation into TAG (47).
In the current study, the ACSL1 deficiency did not protect
mice from diet-induced hepatic steatosis; however, in iso-
lated hepatocytes, [14C]oleate incorporation into TAG was
diminished by 20%. Although our findings suggest that
ACSL1 is not critical for hepatic TAG synthesis, it is possible
that Acsl1L/ liver had adapted to the ACSL1 deficiency by
altering the transcription of genes that are involved in the
uptake and/or metabolism of lipids.
FIGURE 7. FA composition of neutral lipids from Acsl1L/ and control
livers. TAG (A) and CE (B) from livers of mice fed a high fat diet (HFD) or a
control diet (SD) for 14 weeks were extracted and analyzed (Lipomics Tech-
nologies, Inc). Data show means  S.E. from five mice/group. *, p  0.05 versus
control mice fed the same diet (two-way ANOVA). #, p  0.05; ##, p  0.01
versus 10% fat control diet in the same genotype (two-way ANOVA).
FIGURE 8. Euglycemic-hyperinsulinemic clamp study. Control (KO) and
Acsl1L/ mice fed a high fat diet for 3 weeks were studied after 16 h of food
deprivation. With an infusion of 2.5 milliunits of insulin/kg/min, plasma glu-
cose was maintained by an intravenous variable 20% glucose infusion, and
rates were determined for glucose infusion rate and peripheral glucose
uptake (A), basal and clamp hepatic glucose output (B), and glycolysis and
glycogen synthesis (C). Results are expressed as means  S.E. (n 	 10 for each
genotype).
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Despite the lack of difference in plasma -hydroxybutyrate
concentration between genotypes at baseline, after fasting for
24 h, or after feeding low or high fat diets, a defect in -oxida-
tion is supported by several observations. First,Acsl1mRNA in
liver is up-regulated by PPAR, a major transcription factor
that increases the expression of genes involved in FA -oxida-
tion. Second, despite the low, but significant, 4.5% decrease in
incorporation of [14C]oleate into ASM in isolated hepatocytes,
the 50–58% decreases in liver C18-carnitines are consistent
with a reduced flux of acyl-CoAs into the pathway ofmitochon-
drial -oxidation (31), and the 2-fold increase in C8:0-carnitine
and the 91% increase in acyl-CoA oxidase-1 mRNA suggest a
compensatory increase of FA oxidation in peroxisomes. Taken
as a whole, our data suggest that both TAG synthesis and -ox-
idation of long chain FA are impaired in Acsl1L/ liver.
In the context of excess TAG stores in nonadipose tissues,
increases in acyl-CoA, DAG, and ceramide have each been
linked to insulin resistance (10–12). In Acsl1L/ mice fed a
high fat diet, hepatic total acyl-CoA content and major acyl-
CoA species were 25% lower than in controls, andwewondered
whether the mice would be protected from developing insulin
resistance. The ACSL1 deficiency also caused an increase in
hepatic LPA content and a decrease in several DAG species but
did not change the total amount of DAG. Despite these alter-
ations in lipid intermediates, Acsl1L/ mice were normal in
their glucose metabolism, in glucose and insulin tolerance, and
in the ability of insulin to stimulate AKT phosphorylation.
When challenged with a 45% fat diet for 15 weeks, Acsl1L/
mice became as obese and insulin-resistant as control mice.
Further, a euglycemic-hyperinsulinemic clamp study showed
no significant differences between the genotypes in hepatic or
whole body insulin sensitivity in young mice fed a high fat diet
for 3weeks. Aprevious study showed that an increase in hepatic
acyl-CoA content does not result in insulin resistance (17); our
current study suggests that a decrease in acyl-CoA content does
not protect against insulin resistancewhen liverTAGcontent is
elevated.
In summary, this is the first knock-out model designed to
study the role of ACSL1 in liver and in whole bodymetabolism.
Despite the absence of hepatic ACSL1, a 50% decrease in ACSL
specific activity, and a 25–35% decrease in acyl-CoA content,
no obvious changes were observed in liver morphology or
appearance, organ weights, or plasma lipid concentrations, and
Acsl1L/ mice were not protected from diet-induced hepatic
steatosis. Small, but consistent changes were present in the FA
composition of the major phospholipids, and both TAG syn-
thesis and -oxidation were impaired.
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